Results 111 to 120 of about 14,833,612 (178)

Retraction for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. [PDF]

open access: yesJ Clin Invest
Xu H   +22 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Dihydrotanshinone I Inhibits Pancreatic Cancer Progression via Hedgehog/Gli Signal Pathway.

Current Cancer Drug Targets, 2023
INTRODUCTION Pancreatic cancer is highly fatal and its incidence is rising worldwide. Its poor prognosis is attributed to a lack of effective diagnostic and therapeutic strategies.
Wenqian Huang   +5 more
semanticscholar   +3 more sources

Dihydrotanshinone I–Induced CYP1 Enzyme Inhibition and Alteration of Estradiol Metabolism

Drug Metabolism and Disposition, 2023
Dihydrotanshinone I (DHTI) is a pharmacologically active component occurring in the roots of the herbal medicine Salvia miltiorrhiza Bunge. This study investigated DHTI-induced inhibition of CYP1A1, CYP1A2, and CYP1B1 with the aim to determine the ...
Ying Liu   +10 more
semanticscholar   +3 more sources

Home - About - Disclaimer - Privacy